HK1177461A1 - -氯- -吡啶基甲氧基 苯基 氨基 -氰基- -乙氧基- -喹啉基 -甲基吡咯烷- -基 丙- -烯酰胺的可藥用的鹽、其製備方法及其在醫藥上的應用 - Google Patents

-氯- -吡啶基甲氧基 苯基 氨基 -氰基- -乙氧基- -喹啉基 -甲基吡咯烷- -基 丙- -烯酰胺的可藥用的鹽、其製備方法及其在醫藥上的應用

Info

Publication number
HK1177461A1
HK1177461A1 HK13104640.1A HK13104640A HK1177461A1 HK 1177461 A1 HK1177461 A1 HK 1177461A1 HK 13104640 A HK13104640 A HK 13104640A HK 1177461 A1 HK1177461 A1 HK 1177461A1
Authority
HK
Hong Kong
Prior art keywords
pyridylmethoxy
enamide
methylpyrrolidin
quinolyl
prop
Prior art date
Application number
HK13104640.1A
Other languages
English (en)
Inventor
李心王斌
Original Assignee
上海恒瑞醫藥有限公司 上海市 江蘇恒瑞醫藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海恒瑞醫藥有限公司 上海市 江蘇恒瑞醫藥股份有限公司 filed Critical 上海恒瑞醫藥有限公司 上海市 江蘇恒瑞醫藥股份有限公司
Publication of HK1177461A1 publication Critical patent/HK1177461A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK13104640.1A 2011-03-11 2013-04-17 -氯- -吡啶基甲氧基 苯基 氨基 -氰基- -乙氧基- -喹啉基 -甲基吡咯烷- -基 丙- -烯酰胺的可藥用的鹽、其製備方法及其在醫藥上的應用 HK1177461A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011100623598A CN102675287A (zh) 2011-03-11 2011-03-11 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
PCT/CN2012/071015 WO2012122865A2 (zh) 2011-03-11 2012-02-10 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
HK1177461A1 true HK1177461A1 (zh) 2013-08-23

Family

ID=46807903

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13104640.1A HK1177461A1 (zh) 2011-03-11 2013-04-17 -氯- -吡啶基甲氧基 苯基 氨基 -氰基- -乙氧基- -喹啉基 -甲基吡咯烷- -基 丙- -烯酰胺的可藥用的鹽、其製備方法及其在醫藥上的應用

Country Status (12)

Country Link
US (1) US20130338190A1 (zh)
EP (1) EP2684877B1 (zh)
JP (1) JP6192544B2 (zh)
KR (1) KR101871889B1 (zh)
CN (2) CN102675287A (zh)
ES (1) ES2605564T3 (zh)
HK (1) HK1177461A1 (zh)
PL (1) PL2684877T3 (zh)
PT (1) PT2684877T (zh)
RU (1) RU2583056C2 (zh)
TW (1) TWI530288B (zh)
WO (1) WO2012122865A2 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103539783A (zh) * 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
EP3378478B1 (en) * 2016-01-27 2022-05-11 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition comprising quinoline derivative or salt thereof
CN107405345A (zh) 2016-01-27 2017-11-28 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物或其盐的药物组合物的制备方法
CN112426424A (zh) * 2016-01-28 2021-03-02 江苏恒瑞医药股份有限公司 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途
CA3021471A1 (en) 2016-04-28 2017-11-02 Guaili Wu Method for preparing tyrosine kinase inhibitor and derivative thereof
CN107638424B (zh) * 2016-07-20 2022-05-27 江苏恒瑞医药股份有限公司 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗癌症的药物中的用途
TW201827050A (zh) * 2017-01-22 2018-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Egfr/her2抑制劑聯合嘧啶類抗代謝藥物的用途
KR20200072491A (ko) 2017-10-18 2020-06-22 지앙수 헨그루이 메디슨 컴퍼니 리미티드 티로신 키나제 억제제 및 이의 중간체의 제조 방법
KR20200078561A (ko) 2017-10-24 2020-07-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 퀴놀린 유도체를 함유하는 약학 조성물
JP2021503506A (ja) * 2017-11-20 2021-02-12 テリジーン リミテッドTeligene Ltd. (e)−n−(3−シアノ−7−エトキシ−4−((4−フェノキシフェニル)アミノ)キノリン−6−イル)−4−(ジメチルアミノ)ブタ−2−エンアミドのマレイン酸塩及びその結晶形態
US10857146B2 (en) 2018-08-21 2020-12-08 Jiangsu Hengrui Medicine Co., Ltd. Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor
CN110960529A (zh) * 2018-09-30 2020-04-07 江苏恒瑞医药股份有限公司 一种降低了毒性杂质含量的酪氨酸激酶抑制剂的原料药
MX2021004600A (es) * 2018-10-22 2021-06-15 Jiangsu Hengrui Medicine Co Forma cristalina del inhibidor de maleato de tirosina quinasa y metodo de preparacion para el mismo.
CN111821304A (zh) * 2019-04-16 2020-10-27 江苏恒瑞医药股份有限公司 酪氨酸激酶抑制剂联合长春碱类药物在制备预防或治疗肿瘤疾病的药物中的用途
TW202115027A (zh) * 2019-08-30 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 低雜質含量的酪胺酸激酶抑制劑
CN112279838B (zh) * 2020-10-29 2021-07-13 苏州富士莱医药股份有限公司 一种吡咯替尼的制备方法
CN114409584A (zh) * 2022-03-08 2022-04-29 重庆医药高等专科学校 一种1-甲基吡咯烷-2-甲醛的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
KR100486394B1 (ko) * 1999-11-16 2005-04-29 쉬바르츠파르마에이지 3,3-디페닐-프로필아민의 신규한 유도체의 안정한 염
KR20050044599A (ko) * 2001-11-27 2005-05-12 와이어쓰 홀딩스 코포레이션 Egf-r 및 her2 키나아제의 억제제로서의3-시아노퀴놀린
DE10307165A1 (de) * 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
CN100540552C (zh) 2007-02-01 2009-09-16 中国药科大学 3-氰基喹啉衍生物、其制备方法及其医药用途
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101824029A (zh) * 2009-03-05 2010-09-08 厦门艾德生物医药科技有限公司 酪氨酸激酶不可逆抑制剂、其药物组合物及其用途
CN102020639A (zh) * 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
CN107441058A (zh) * 2009-11-09 2017-12-08 惠氏有限责任公司 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途

Also Published As

Publication number Publication date
JP6192544B2 (ja) 2017-09-06
JP2014507448A (ja) 2014-03-27
ES2605564T3 (es) 2017-03-15
TWI530288B (zh) 2016-04-21
EP2684877A4 (en) 2014-08-06
RU2583056C2 (ru) 2016-05-10
TW201236684A (en) 2012-09-16
PL2684877T3 (pl) 2017-05-31
CN102675287A (zh) 2012-09-19
WO2012122865A3 (zh) 2012-11-08
KR101871889B1 (ko) 2018-06-27
EP2684877A2 (en) 2014-01-15
EP2684877B1 (en) 2016-10-19
PT2684877T (pt) 2017-01-18
WO2012122865A2 (zh) 2012-09-20
RU2013143381A (ru) 2015-04-20
CN102933574B (zh) 2014-10-01
US20130338190A1 (en) 2013-12-19
KR20140009418A (ko) 2014-01-22
CN102933574A (zh) 2013-02-13

Similar Documents

Publication Publication Date Title
HK1177461A1 (zh) -氯- -吡啶基甲氧基 苯基 氨基 -氰基- -乙氧基- -喹啉基 -甲基吡咯烷- -基 丙- -烯酰胺的可藥用的鹽、其製備方法及其在醫藥上的應用
IL229199A (en) N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs
EP2769976B8 (en) Hydroxamic acid compound containing quinolyl and preparation method thereof, and pharmaceutical composition containing this compound and use thereof
CY1118839T1 (el) Επικαλυμμενη φαρμακευτικη συνθεση που περιεχει ρεγοραφενιμπη
BR112014003802A2 (pt) composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
BR112014008126A2 (pt) composto, método para o tratamento, composição farmacêutica, utilização de um composto e invenção
CL2013001381A1 (es) Compuestos derivados de hidroxi-amida pirimidina, inhibidores de la proteina deacetilasa hdac6; composicion farmaceutica; combinación farmaceutica; metodos de uso para el tratamiento de una enfermedad proliferativa o cancer; un kit
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
IL231495B (en) N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide compounds or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of osteoporosis
BR112013009970A2 (pt) método para determinar uma característica do ritmo circadiano de um paciente.
GB2505860B (en) Aripiprazole medicament formulation and preparation method therefor
ZA201307688B (en) Pharmaceutically acceptable cocrystals of n-[2-(7-methoxy-1-naphtyl)ethyl] acetamide and methods of their preparation
IL230487B (en) 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them
CY1123700T1 (el) Παιδιατρικη φαρμακοτεχνικη μορφη
IL230484A (en) "6- (n- (7-Chloro-1-Hydroxy-1, 3-Dihydrobenzo [c] [1,2] Oxaborol-5-Yl) - Methylbenzoforan-3 - Carbamamide and a Pharmaceutical Preparation
EP2781512A4 (en) OXADIAZOLE COMPOUND AND PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF
ZA201303695B (en) Pharmaceutical composition comprising citrate and bicarbonate salts,and use thereof for treating cystinuria
BR112012033121A2 (pt) métodos e composições farmacêuticas para o tratamento de infecções do trato respiratório.
BR112013019775A2 (pt) composto, composição farmacêutica e método para tratar declínio cognitivo ou doença de alzheimer em um paciente
BR112013017184A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para evitar, tratar ou melhorar doenças
MX2013006031A (es) Formulacion liposomal de dalcetrapib.
HUP1100351A2 (en) Process for the preparation of (5alpha,17beta)-n-[2,5-bis-(trifluoromethyl)-phenyl]-3-oxo-4-aza-5-androst-1-en-17-carboxylic amide

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20240212